Current studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing promising results in managing obesity and diabetes non-insulin-dependent disease. Initial evidence suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/